Literature DB >> 17589197

Effect of tenofovir on renal glomerular and tubular function.

Christoph A Fux1, Anna Christen, Susanne Zgraggen, Markus G Mohaupt, Hansjakob Furrer.   

Abstract

To evaluate tenofovir-related nephropathy, we quantified calculated glomerular filtration rates (GFR) and renal tubular function in 46 tenofovir-treated patients and 25 without tenofovir. We also analysed patients who stopped tenofovir for drug-related nephrotoxicity at our clinic. Tenofovir use combined with non-nucleoside reverse transcriptase inhibitors, but not with protease inhibitors, resulted in a significant increase in calculated GFR. Tenofovir use was associated with significantly lower phosphatemia and a marginally increased fractional excretion of uric acid, but no other signs of tubulopathy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17589197     DOI: 10.1097/QAD.0b013e328216f15b

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  15 in total

1.  Risk of hip fracture associated with hepatitis C virus infection and hepatitis C/human immunodeficiency virus coinfection.

Authors:  Vincent Lo Re; Jessica Volk; Craig W Newcomb; Yu-Xiao Yang; Cristin P Freeman; Sean Hennessy; Jay R Kostman; Pablo Tebas; Mary B Leonard; A Russell Localio
Journal:  Hepatology       Date:  2012-10-14       Impact factor: 17.425

2.  Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factors.

Authors:  Carl Grunfeld; Donald P Kotler; Donna K Arnett; Julian M Falutz; Steven M Haffner; Paul Hruz; Henry Masur; James B Meigs; Kathleen Mulligan; Peter Reiss; Katherine Samaras
Journal:  Circulation       Date:  2008-06-19       Impact factor: 29.690

3.  Inflammation status in HIV-positive individuals correlates with changes in bone tissue quality after initiation of ART.

Authors:  E Lerma-Chippirraz; Marta Pineda-Moncusí; A González-Mena; Jade Soldado-Folgado; H Knobel; M Trenchs-Rodríguez; A Díez-Pérez; Todd T Brown; N García-Giralt; R Güerri-Fernández
Journal:  J Antimicrob Chemother       Date:  2019-05-01       Impact factor: 5.790

4.  Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial.

Authors:  Peter L Havens; Charles B Stephensen; Rohan Hazra; Patricia M Flynn; Craig M Wilson; Brandy Rutledge; James Bethel; Cynthia G Pan; Leslie R Woodhouse; Marta D Van Loan; Nancy Liu; Jorge Lujan-Zilbermann; Alyne Baker; Bill G Kapogiannis; Kathleen Mulligan
Journal:  Clin Infect Dis       Date:  2012-01-19       Impact factor: 9.079

5.  Renal events among women treated with tenofovir/emtricitabine in combination with either lopinavir/ritonavir or nevirapine.

Authors:  Albert Mwafongo; Kondwani Nkanaunena; Yu Zheng; Evelyn Hogg; Wadzanai Samaneka; Lloyd Mulenga; Abraham Siika; Judith Currier; Shahin Lockman; Michael D Hughes; Mina Hosseinipour
Journal:  AIDS       Date:  2014-05-15       Impact factor: 4.177

6.  Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency?

Authors:  Peter L Havens; Jennifer J Kiser; Charles B Stephensen; Rohan Hazra; Patricia M Flynn; Craig M Wilson; Brandy Rutledge; James Bethel; Cynthia G Pan; Leslie R Woodhouse; Marta D Van Loan; Nancy Liu; Jorge Lujan-Zilbermann; Alyne Baker; Bill G Kapogiannis; Catherine M Gordon; Kathleen Mulligan
Journal:  Antimicrob Agents Chemother       Date:  2013-09-03       Impact factor: 5.191

7.  Tenofovir renal toxicity targets mitochondria of renal proximal tubules.

Authors:  James J Kohler; Seyed H Hosseini; Amy Hoying-Brandt; Elgin Green; David M Johnson; Rodney Russ; Dung Tran; C Michael Raper; Robert Santoianni; William Lewis
Journal:  Lab Invest       Date:  2009-03-09       Impact factor: 5.662

8.  Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects.

Authors:  Koen K A Van Rompay; Lucie Durand-Gasselin; Laurie L Brignolo; Adrian S Ray; Kristina Abel; Tomas Cihlar; Abigail Spinner; Christopher Jerome; Joseph Moore; Brian P Kearney; Marta L Marthas; Hans Reiser; Norbert Bischofberger
Journal:  Antimicrob Agents Chemother       Date:  2008-06-23       Impact factor: 5.191

9.  Low Risk of Proximal Tubular Dysfunction Associated With Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis in Men and Women.

Authors:  Kenneth Mugwanya; Jared Baeten; Connie Celum; Deborah Donnell; Thomas Nickolas; Nelly Mugo; Andrea Branch; Jordan Tappero; James Kiarie; Allan Ronald; Michael Yin; Christina Wyatt
Journal:  J Infect Dis       Date:  2016-03-29       Impact factor: 5.226

10.  Vitamin D3 supplementation increases fibroblast growth factor-23 in HIV-infected youths treated with tenofovir disoproxil fumarate.

Authors:  Peter L Havens; Rohan Hazra; Charles B Stephensen; Jennifer J Kiser; Patricia M Flynn; Craig M Wilson; Brandy Rutledge; James Bethel; Cynthia G Pan; Leslie R Woodhouse; Marta D Van Loan; Nancy Liu; Jorge Lujan-Zilbermann; Alyne Baker; Bill G Kapogiannis; Catherine M Gordon; Kathleen Mulligan
Journal:  Antivir Ther       Date:  2014-02-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.